Zhao et al. reported among 43 patients treated with sotorasib - including 36 NSCLC patients - that exceptional responders (i.e., defined as a complete response or a partial response lasting more than 12 months) tend to have a lower plasma KRAS G12C allele frequency and a lower tumor burden at baseline compared to other patients (90). Here, KRAS is linked to non-small cell lung carcinoma.